All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (Current) smoker (Former) smoker (never) Teff high Teff low
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
lung cancer : non small cell (NSCLC), atezolizumab based treatment vs. non platinum-based chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results OAK (all population), 2016 0.80 [0.70; 0.92]
OAK (PDL1 TC 1/2/3), 2016 0.77 [0.64; 0.92]
POPLAR, 2016 0.73 [0.53; 1.00]
0.78 [0.71 ; 0.87 ] OAK (all population), 2016, OAK (PDL1 TC 1/2/3), 2016, POPLAR, 2016 3 0% 2,196 moderate not evaluable progression or deaths (PFS)detailed results OAK (all population), 2016 0.96 [0.85; 1.08]
OAK (PDL1 TC 1/2/3), 2016 0.87 [0.74; 1.03]
POPLAR, 2016 0.94 [0.72; 1.23]
0.93 [0.85 ; 1.02 ] OAK (all population), 2016, OAK (PDL1 TC 1/2/3), 2016, POPLAR, 2016 3 0% 2,196 moderate not evaluable DORdetailed results OAK (PDL1 TC 1/2/3), 2016 9.61 [3.07; 30.08]
9.61 [3.07 ; 30.08 ] OAK (PDL1 TC 1/2/3), 2016 1 0% 107 NA not evaluable objective responses (ORR)detailed results OAK (all population), 2016 1.19 [0.85; 1.67]
OAK (PDL1 TC 1/2/3), 2016 1.41 [0.93; 2.14]
POPLAR, 2016 0.99 [0.52; 1.91]
1.23 [0.96 ; 1.57 ] OAK (all population), 2016, OAK (PDL1 TC 1/2/3), 2016, POPLAR, 2016 3 0% 2,196 moderate not evaluable AE (any grade)detailed results OAK (all population), 2016 0.66 [0.39; 1.13]
POPLAR, 2016 0.87 [0.26; 2.93]
0.69 [0.42 ; 1.13 ] OAK (all population), 2016, POPLAR, 2016 2 0% 1,464 moderate not evaluable AE (grade 3-4)detailed results OAK (all population), 2016 0.51 [0.41; 0.65]
POPLAR, 2016 0.60 [0.38; 0.97]
0.53 [0.43 ; 0.65 ] OAK (all population), 2016, POPLAR, 2016 2 0% 1,464 moderate not evaluable AE leading to death (grade 5)detailed results OAK (all population), 2016 0.67 [0.30; 1.53]
POPLAR, 2016 1.15 [0.34; 3.85]
0.80 [0.40 ; 1.57 ] OAK (all population), 2016, POPLAR, 2016 2 0% 1,464 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results OAK (all population), 2016 0.58 [0.45; 0.75]
POPLAR, 2016 0.29 [0.14; 0.61]
0.45 [0.24 ; 0.87 ] OAK (all population), 2016, POPLAR, 2016 2 66% 1,464 moderate not evaluable SAE (any grade)detailed results POPLAR, 2016 1.05 [0.64; 1.73]
1.05 [0.64 ; 1.73 ] POPLAR, 2016 1 0% 277 NA not evaluable SAE (grade 3-4)detailed results OAK (all population), 2016 1.03 [0.80; 1.31]
1.03 [0.80 ; 1.31 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable TRAE (any grade)detailed results OAK (all population), 2016 0.29 [0.22; 0.39]
POPLAR, 2016 0.27 [0.15; 0.51]
0.29 [0.22 ; 0.38 ] OAK (all population), 2016, POPLAR, 2016 2 0% 1,464 moderate not evaluable TRAE (grade 3-4)detailed results OAK (all population), 2016 0.23 [0.18; 0.31]
POPLAR, 2016 0.20 [0.11; 0.38]
0.23 [0.18 ; 0.29 ] OAK (all population), 2016, POPLAR, 2016 2 0% 1,464 moderate not evaluable TRAE leading to death (grade 5)detailed results OAK (all population), 2016 0.47 [0.02; 14.16]
POPLAR, 2016 0.31 [0.03; 3.04]
0.36 [0.05 ; 2.35 ] OAK (all population), 2016, POPLAR, 2016 2 0% 1,464 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results POPLAR, 2016 0.07 [0.02; 0.29]
0.07 [0.02 ; 0.29 ] POPLAR, 2016 1 0% 277 NA not evaluable Alopecia AE (grade 3-4)detailed results OAK (all population), 2016 0.47 [0.02; 14.16]
0.47 [0.02 ; 14.16 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Anaemia AE (grade 3-4)detailed results OAK (all population), 2016 0.39 [0.21; 0.73]
0.39 [0.21 ; 0.73 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Arthralgia AE (grade 3-4)detailed results OAK (all population), 2016 2.86 [0.30; 27.54]
2.86 [0.30 ; 27.54 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Asthenia AE (grade 3-4)detailed results OAK (all population), 2016 0.58 [0.24; 1.41]
0.58 [0.24 ; 1.41 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Back pain AE (grade 3-4)detailed results OAK (all population), 2016 1.67 [0.49; 5.73]
1.67 [0.49 ; 5.73 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Constipation AE (grade 3-4)detailed results OAK (all population), 2016 1.90 [0.17; 21.02]
1.90 [0.17 ; 21.02 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Cough AE (grade 3-4)detailed results OAK (all population), 2016 1.90 [0.17; 21.02]
1.90 [0.17 ; 21.02 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Decreased appetite AE (grade 3-4)detailed results OAK (all population), 2016 0.21 [0.04; 0.97]
0.21 [0.04 ; 0.97 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Diarrhoea AE (grade 3-4)detailed results OAK (all population), 2016 0.34 [0.11; 1.08]
0.34 [0.11 ; 1.08 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Dysgeusia AE (grade 3-4)detailed results OAK (all population), 2016 0.95 [0.02; 47.91]
0.95 [0.02 ; 47.91 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Dyspnoea AE (grade 3-4)detailed results OAK (all population), 2016 1.02 [0.49; 2.13]
1.02 [0.49 ; 2.13 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Fatigue AE (grade 3-4)detailed results OAK (all population), 2016 0.69 [0.37; 1.31]
0.69 [0.37 ; 1.31 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results OAK (all population), 2016 0.01 [0.00; 0.10]
0.01 [0.00 ; 0.10 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Myalgia AE (grade 3-4)detailed results OAK (all population), 2016 0.24 [0.03; 2.12]
0.24 [0.03 ; 2.12 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Nausea AE (grade 3-4)detailed results OAK (all population), 2016 1.90 [0.35; 10.44]
1.90 [0.35 ; 10.44 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Neutropenia AE (grade 3-4)detailed results OAK (all population), 2016 0.03 [0.01; 0.11]
0.03 [0.01 ; 0.11 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results OAK (all population), 2016 0.07 [0.00; 1.18]
0.07 [0.00 ; 1.18 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results OAK (all population), 2016 0.32 [0.03; 3.04]
0.32 [0.03 ; 3.04 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Pyrexia AE (grade 3-4)detailed results OAK (all population), 2016 0.95 [0.06; 15.21]
0.95 [0.06 ; 15.21 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Stomatitis AE (grade 3-4)detailed results OAK (all population), 2016 0.08 [0.01; 0.66]
0.08 [0.01 ; 0.66 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Vomiting AE (grade 3-4)detailed results OAK (all population), 2016 0.47 [0.09; 2.59]
0.47 [0.09 ; 2.59 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-05 19:25 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334
- treatments: 851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866
